

-D HIS

(FILE 'HOME' ENTERED AT 15:30:35 ON 13 SEP 2001)

FILE 'CROPU, DGENE, DPCI, ENCOMPPAT, ENCOMEPAT2, EUROPATFULL, HCAOLD,
HCAPLUS, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE,
PATOSEP, PATOSWO, PCTFULL, PIRA, RAPRA, SYNTHLINE, TULSA, TULSA2,
USPATEFULL, WPIDS' ENTERED AT 15:31:11 ON 13 SEP 2001

| | |
|----|--|
| L1 | 614 S (DRUG OR PHARMACEUTICAL) (L) BIFUNCT? (L) BIODISTRIBUT? |
| L2 | 611 DUP REM L1 (3 DUPLICATES REMOVED) |
| L3 | 153 S L2 AND DALTON |
| L4 | 123 S L3 AND PY<=1999 |
| L5 | 116 S L4 AND TARGET? |
| L6 | 21 S L5 AND (5000 DALTON# OR 5,000 DALTON# OR 5 KDA OR 5 KILODAL |

NO ANSWER 1 OF 11
 ACCESSION NUMBER: 199066951 POTFULL
 TITLE (ENGLISH): USE OF BI-SPECIFIC ANTIBODIES FOR PRE
TARGETING DIAGNOSIS AND
 THERAPY
 TITLE (FRENCH): UTILISATION D'ANTICORPS BI-SPECIFIQUES POUR DIAGNOSTIC
 ET
 THERAPIE DE PRE CIBLAGE
 INVENTOR(S): HANSEN, Hans, J.; GRIFFITHS, Gary, L.; LEUNG, Shui-on;
 MURBLIDE, William, J.; QU, Zhengxing
 PATENT ASSIGNEE(S): IMMUNOMEDICS, INC.
 LANGUAGE OF PUBL.: English
 LANGUAGE OF FILING: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER KIND DATE

WO 9966951 A2 19991229

DESIGNATED STATES: AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
 EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
 KR KZ LC LE LF LS LT LV MD MG MK MN MW NX NO NZ PL
 PT RO RU SD SE SG SI SJ SL TC TM TR TT UA UG US UZ VN
 YU ZA ZW GH GM EE LS MW SD SL SG UG ZW AM AZ BY KG KZ
 MD RU TJ TH AT BE CH CY DE DK EE FI FR GB GR IE IT LU
 LI NL PT SG SE SJ CF CG CI CM GA GN GW ML MR NE SN TD
 TH

APPLICATION INFO.: 99 1999 US13879 19990622
 PRIORITY (ORIGINAL): 99 1998 60,090142 19980622
 99 1998 60,104156 1998 014

ABEN The present invention relates to a bi-specific antibody or
 antibody fragment having at least one arm that specifically binds a
targeted tissue and at least one other arm that specifically
 binds a
targetable conjugate. The **targetable** conjugate
 comprises a carrier
 portion which comprises or bears at least one epitope recognizable by at
 least one arm of said bi-specific antibody or antibody fragment. The
targetable conjugate further comprises one or more therapeutic
 or
 diagnostic agents or enzymes. The invention provides constructs and
 methods for producing the bi-specific antibodies or antibody fragments,
 as well as methods for using them.

ALFR L'invention concerne un anticorps bi-spécifique ou un fragment
 d'anticorps pouvant avoir au moins un bras qui se lie spécifiquement à un
 tissu cible et d'un autre bras qui se lie spécifiquement à un conjugué
 pouvant être visé. Ce dernier comporte une partie vecteur qui comporte
 ou porte au moins un épitope reconnaissable par au moins un bras dudit
 anticorps bi-spécifique ou dudit fragment d'anticorps. Le conjugué
 pouvant être visé comporte également un ou plusieurs agents ou enzymes
 thérapeutiques ou diagnostiques. L'invention concerne également des
 produits de recombinaison et des méthodes de production et d'utilisation
 de ces anticorps bi-spécifiques et de ces fragments d'anticorps.

NO ANSWER 2 OF 21
 ACCESSION NUMBER: 199066957 POTFULL
 TITLE (ENGLISH): INTERNALIZING EBBS ANTIBODIES
 TITLE (FRENCH): ANTICORPS EBBS D'INTERNALISATION
 INVENTOR(S): MARKS, James, D.; POUL, Marie, Alice
 PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
 LANGUAGE OF PUBL.: English

LANGUAGE OF PUBLICATION: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

WO 995367 A1 19991104

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW ME NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT UA US UZ VN
YU ZA ZW ZH ZM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG

APPLICATION INFO.: WO 1999-087395 19990423
PRIORITY ORIGINAL: US 1998 09/082953 19980424
US 1999 09/250036 19990212

ABEN This invention provides novel erbB2-binding internalizing
antibodies. The antibodies, designated F5 and C1, specifically bind to c-
erbB2 antigen and, upon binding, are readily internalized into the cell
bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or
C1 antibodies attached to one or more effector molecules are also
provided.

ABFR L'invention porte sur de nouveaux anticorps d'internalisation
liaison ERBB2. Les anticorps, appelés F5 et C1, se lient spécifiquement
l'antigène c-erbB2 et, lors de la liaison, sont facilement
internalisés dans la cellule supportant le marqueur c-erbB2. L'invention
porte également sur des molécules chimères comprenant les anticorps F5
et/ou C1 liés à une ou plusieurs molécules effectrices.

16 ANSWER 3 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1996004304 PCTFULL
TITLE (ENGLISH): FIBRIN-BINDING PEPTIDES, DNA CODING THEREFOR AND USES
THEREOF
TITLE (FRENCH): PEPTIDES SE FIXANT A LA FIBRINE, A D N LES CODANT ET
LEURS
UTILISATIONS
INVENTOR(S): GOLD, Leslie, I.; ROSTAGNO, Agueda, A.
PATENT ASSIGNEE(S): NEW YORK UNIVERSITY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

WO 9604304 A1 19960215

DESIGNATED STATES: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
SE

APPLICATION INFO.: WO 1995-U39819 19950801
PRIORITY (ORIGINAL): US 1994 8/183857 19940801

ABEN Fibrin-binding molecules are provided which include at least one
peptide essentially corresponding to the 10F1.11F1 module pair of
fibronectin and includes no more of the natural fibronectin molecule
than the C-terminal 11kDa proteolytic fragment. Also disclosed are
nucleic acid molecules encoding the fibrin-binding peptides, methods for
making the peptides, methods for using the peptides in the diagnosis and
treatment of cardiovascular, peripheral vascular, cerebrovascular, and
other conditions associated with fibrin deposition, and assay methods
for detecting a fibrin-binding molecule and for measuring fibrin.

ABFR L'invention concerne des molécules se fixant à la fibrine et
comportant au moins un peptide correspondant essentiellement à la paire
de modules 10 F1 11 F1 de fibronectine et ne comportant pas plus de
molécule de fibronectine naturelle que de fragment protéolytique de

alpha a terminaison et. Elle concerne également des molécules d'acide nucléique codant les peptides se fixant à la fibrine, des procédés de préparation desdits peptides, des procédés d'utilisation desdits peptides dans le diagnostic et le traitement de maladies cardio-vasculaires, vasculaires périphériques et cérébrovasculaires, ainsi que d'autres maladies provoquées par le dépôt de la fibrine, et enfin, des procédés d'analyse pour détecter une molécule se fixant à la fibrine et pour mesurer la fibrine.

LG ANSWER 4 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
 ACCESSION NUMBER: 1995031221 PCTFULL
 TITLE (ENGLISH): SOMATOSTATIN BINDING PEPTIDE-METAL CHELATE CONJUGATES
 TITLE (FRENCH): CONJUGUES PEPTIDE-CHELATE METALLIQUE SE LIANT A LA SOMATOSTATINE
 INVENTOR(S): DEAN, Richard
 PATENT ASSIGNEE(S): DIATECH, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER KIND DATE

WO 9531221 A1 19951123

DESIGNATED STATES: AU CA CN JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1995-US6034 19950512

PRIORITY (ORIGINAL): US 1994-8/241625 19940512

ABEN This invention relates to diagnostic and radiodiagnostic agents, including radiolabeled scintigraphic imaging agents, and therapeutic and radiotherapeutic agents. The invention provides such agents and reagents for preparing such agents, and methods for producing and using such reagents. Specifically, the invention provides radiolabeled imaging agents and non-radioactively labeled imaging agents for imaging sites in a mammalian body and reagents for preparing these imaging agents. The invention also provides radiolabeled therapeutic agents, as well as non-radioactively labeled therapeutic agents, and reagents and methods for preparing these agents. The agents and reagents provided comprise a specific binding peptide, covalently linked to a metal ion-complexing moiety. Reagents, methods and kits for making such reagents, methods for labelling such reagents, and methods for using such labeled reagents are provided.

ABF La présente invention se rapporte à des agents diagnostiques et radiodiagnostiques, y compris des agents d'imagerie scintigraphiques radiomarqués, ainsi que des agents thérapeutiques et radiothérapeutiques. L'invention se rapporte à ces agents et à des réactifs servant à préparer ces agents, ainsi qu'à des procédés de production et d'utilisation de ces réactifs. L'invention se rapporte spécifiquement à des agents d'imagerie radiomarqués et à des agents d'imagerie marqués non radioactivement servant à former des images de sites du corps d'un mammifère, et à des réactifs permettant de préparer ces agents d'imagerie. L'invention se rapporte également à des agents thérapeutiques radiomarqués et à des agents thérapeutiques marqués non radioactivement, et à des réactifs et des procédés permettant de préparer ces agents. Les agents et les réactifs décrits comprennent un peptide de liaison spécifique, lié de manière covalente à une fraction de complexage d'ion métal. On décrit également des réactifs, des procédés et des kits permettant de préparer ces réactifs, des procédés de marquage de ces réactifs ainsi que des procédés d'utilisation de ces réactifs marqués.

LG ANSWER 6 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
 ACCESSION NUMBER: 1995029798 PCTFULL
 TITLE (ENGLISH): TECHNETIUM-99m LABELED IMAGING AGENTS

INVENTOR(S): AGENTS D'IMAGERIE MARQUES AU TECHNETIUM 99m
 DEAN, Richard, T.; LISTER JAMES, John; McBRIDE,
 William
 PATENT ASSIGNEE(S): PLATECH, INC.; DEAN, Richard, T.; LISTER JAMES, John;
 McBRIDE, William
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER KIND DATE

WO 9529708 A1 19951109

DESIGNATED STATES: AU CA CN JP US AT BE CH DE DK ES FR GB GR IE IT LU MC
 NL PT SE

APPLICATION INFO.: WO 1995-US5340 19950501

PRIORITY (ORIGINAL): US 1994-8/256402 19940502

ABEN This invention relates to radiolabeled scintigraphic imaging
 agents and reagents for preparing such imaging agents and methods for
 producing and using such reagents. Specifically, the invention relates
 to reagents for preparing scintigraphic imaging agents for imaging sites
 in a mammalian body comprising a specific binding compound including
 specific-binding peptide embodiments thereof, covalently linked to a
 radiolabel complexing moiety. Reagents, methods and kits for making such
 reagents, and methods for using such reagents labeled with technetium-
 99m (Tc-99m) via Tc-99m complexing moieties comprising said reagents,
 are provided.

ABF Agents d'imagerie scintigraphique radiomarques et reactifs pour
 la preparation d'agents d'imagerie de ce type, et procedes de production
 et de mise en oeuvre de ces reactifs. Il s'agit plus precisement de
 reactifs pour la preparation d'agents d'imagerie scintigraphique
 destines a l'imagerie de certains sites dans le corps d'un mammitere,
 comportant un compose a liaison specifique, et, notamment, des formes
 peptidiques a liaison specifique de celui-ci, liees de maniere covalente
 a une fraction de complexion de radiomarqueurs. On a prevu des reactifs,
 des procedes et des troussees pour la fabrication de reactifs de ce type,
 et des procedes de mise en oeuvre de ces reactifs marques au technetium
 99m (Tc-99m) par l'intermediaire de fractions de complexion de Tc-99m
 comportant ces reactifs.

L6 ANSWER 6 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
 ACCESSION NUMBER: 1995015979 PCTFULL
 TITLE (ENGLISH): PRETARGETING METHODS AND COMPOUNDS
 TITLE (FRENCH): PROCEDES ET COMPOSES DE PRECIBLAGE
 INVENTOR(S): THEODORE, Louis, J.; MEYER, Damon, L.; MALLETT,
 Robert, W.; KASINA, Sudhakar; RENO, John, M.;
 AZWORTHY, Donald, B.; GUSTAVSON, Linda, M.

PATENT ASSIGNEE(S): NEORX CORPORATION

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

WO 9515979 A1 19950615

DESIGNATED STATES: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1994-US14174 19941207

PRIORITY (ORIGINAL): US 1993-8/103188 19931207

ABEN Methods, compounds, compositions and kits that relate to
 pre-targeted delivery of diagnostic and therapeutic agents are disclosed.

ABF L'invention concerne des procedes, des composes, des compositions
 et des kits presentant une efficacite pour l'administration pre-ciblee
 d'agents diagnostiques et therapeutiques.

L6 ANSWER 7 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent

ACCESSION NUMBER: 1995-0041 PCTFULL
 TITLE (ENGLISH): POLYMERIC CARRIERS FOR NON-COVALENT DRUG
 CONJUGATION
 TITLE (FRENCH): VEHICULES POLYMERES POUR LA CONJUGATION NON COVALENTE
 DE
 MEDICAMENTS
 INVENTOR(S): GUSTAVSON, Linda, M.; ANDERSON, David, C.; MORGAN,
 Alton, C., Jr.
 PATENT ASSIGNEE(S): NEORX CORPORATION
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER KIND DATE

WO 9503064 A1 19950202

DESIGNATED STATES: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 APPLICATION INFO.: WO 1994-US7734 19940712
 PRIORITY (ORIGINAL): US 1993-8/095515 19930726
 ABEN Polymeric carriers are polypeptides comprising at least one **drug**

binding domain that non-covalently binds a **drug**. A polymeric
 carrier may
 be attached to an antibody specific for desired **target** cells to
 form
 immunoconjugates that deliver a **drug** to the **target**
 cells in vivo. A
 polymeric carrier may be attached to a proteinaceous or a non
 proteinaceous ligand or anti-ligand to form a conjugate useful in
 pretargeting protocols to deliver a **drug** to **target**
 cells in vivo. The
 carriers are derived from **drug** binding proteins and produced
 through
 peptide synthesis or recombinant DNA technology.

ABF Des vehicules polymeres sont composes de polypeptides comprenant
 au moins un domaine de liaison de medicament presentant une liaison non
 covalente par rapport a un medicament. Un vehicule polymere peut etre
 fixe a un anticorps specifique contre des cellules cibles donnees pour
 former des immunoconjugues qui apportent un medicament in vivo aux
 cellules cibles. Un vehicule polymere peut etre fixe a un ligand ou anti-
 ligand proteinique ou non-proteinique afin de former un conjugue apte a
 etre utilise dans des protocoles de pre-ciblage pour apporter un
 medicament in vivo a des cellules cibles. Ces vehicules sont derives de
 proteines de liaison de medicaments et produits par la synthese de
 peptides ou la technologie de recombinaison d'ADN.

L6 ANSWER 5 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
 ACCESSION NUMBER: 1994014976 PCTFULL
 TITLE (ENGLISH): IMMUNE RESPONSE MODULATOR COMPLEX, AND USES THEREOF
 TITLE (FRENCH): COMPLEXE MODULATEUR DE LA REPONSE IMMUNITAIRE, ET SES
 UTILISATIONS
 INVENTOR(S): PIZZO, Salvatore, V.; CHU, Charleen, T.; OURY, Tim, D.
 PATENT ASSIGNEE(S): DUKE UNIVERSITY; PIZZO, Salvatore, V.; CHU, Charleen,
 T.; OURY, Tim, D.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER KIND DATE

WO 9414976 A1 19940707

DESIGNATED STATES: AU BR BG BR BY CA CZ FI HU JP KR KZ LK MG MW NO NZ
 PL RO RU SD SK UA AT BE CH DE DK ES FR GB GR IE IT LU
 MC NL PT SE BF BJ CF CG CI CM GA GN NE SN TD TG

APPLICATION INFO.: WO 1993 025240 19931223
PRIORITY (ORIGINAL): US 1992 7/995383 19921223

ABEN A method of enhancing antigen presentation is disclosed, wherein an antigen is modified by coupling or incorporation with alpha2 macroglobulin (alpha2M), a construct thereof, or a reactive fragment thereof. The antigen so prepared is capable of eliciting enhanced immune response from silent, scarce or weak epitopes. This may comprise an actual activation process, a shift in the dominance to a different epitope by reducing recognition of an immunodominant epitope, or another mechanism. Also included are the antibodies which recognize these epitopes, methods of treatment and use, including the preparation of monovalent and polyvalent vaccines, recombinant alpha2M constructs, and assay techniques and kits for performing such methods.

ABF Est decrit un procede pour stimuler la presentation de l'antigene, dans lequel un antigen est modifie par incorporation ou couplage avec une alpha2 macroglobuline (alpha2M), son produit de recombinaison, ou bien son fragment reactif. L'antigene ainsi prepare est capable de declencher une reponse immunitaire amelioree de la part d'epitopes silencieux, rares ou faibles. Ceci peut consister en un processus d'activation reel, un glissement de dominance en faveur d'un epitope different par diminution de la reconnaissance d'un epitope immunodominant, ou bien un autre mecanisme. Sont egalement decrits les anticorps qui reconnaissent ces epitopes, des procedes de traitement et d'utilisation, notamment la preparation de vaccins monovalents et polyvalents, de produits de recombinaison de alpha2M, ainsi que des techniques et des troussees de dosage pour mettre en oeuvre de tels procedes.

L6 ANSWER 9 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1993025240 PCTFULL
TITLE (ENGLISH): PRETARGETING METHODS AND COMPOUNDS
TITLE (FRENCH): PROCEDES ET COMPOSES DE PRECIBLAGE
INVENTOR(S): AXWORTHY, Donald, B.; THEODORE, Louis, J.; GUSTAVSON, Linda, M.; RENO, John, M.
PATENT ASSIGNEE(S): NEOEX CORPORATION; AXWORTHY, Donald, B.; THEODORE, Louis, J.; GUSTAVSON, Linda, M.; RENO, John, M.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

| | | |
|------------|----|----------|
| WO 9325240 | A2 | 19931223 |
|------------|----|----------|

DESIGNATED STATES: CA JP US US AT BE CH IE DK ES FR GB GR IE IT LU MC NL PT SE

| | | |
|----------------------|------------------|----------|
| APPLICATION INFO.: | WO 1993-US5496 | 19930207 |
| PRIORITY (ORIGINAL): | US 1992-7/995383 | 19921223 |
| | US 1992-7/995381 | 19921223 |
| | US 1992-7/995383 | 19921223 |

ABEN Methods, compounds, compositions and kits that relate to pre-targeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti ligand **targeting** moiety conjugates, **target** cell retention enhancing moieties and additional methods are discussed.

ABF L'invention decrit des procedes, des composees, des compositions et des kits conqus pour la delivrance preciblee d'agents diagnostiques et therapeutiques. En particulier, elle decrit des procedes de marquage radiometallographique de la biotine et de radiohalogenation amelioree de la biotine, ainsi que des composees correspondants. Elle concerne egalement des agents d'elimination, des conjugues de fractions de

embargo anti-ligand, des fractions d'amplicon et de la rétention de cellules cibles, ainsi que des procédés complémentaires.

L6 ANSWER 10 OF 11 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 199301517 PCTFULL
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY
TITLE (FRENCH): COMPOSITIONS ET PROCÉDES DESTINÉS À AMÉLIORER LA LIBÉRATION ET L'ACHÈMÈNEMENT DE MÉDICAMENTS
INVENTOR(S): HALE, Ron, L.; LU, Amy; SOLAS, Dennis; SELICK, Harold, E.; OLDENBURG, Kevin, R.; ZAFFARONI, Alejandro, C.
PATENT ASSIGNEE(S): AFFYMAX TECHNOLOGIES N.V.; HALE, Ron, L.; LU, Amy; SOLAS, Dennis; SELICK, Harold, E.; OLDENBURG, Kevin, R.; ZAFFARONI, Alejandro, C.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

| | | |
|------------|----|----------|
| WO 9325197 | A1 | 19931223 |
|------------|----|----------|

DESIGNATED STATES: AT AU BE BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN NW NL NO PT RO RU SD SE SK UA US US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1993-01651 19930611
PRIORITY (ORIGINAL): US 1992 7,898,219 19920612
US 1993 8,109,463 19930127

ABEN The present invention relates to methods of delivering **pharmaceutical** agents across membranes, including the skin layer or mucosal membranes of a patient. A **pharmaceutical** agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

ABF La présente invention se rapporte à des procédés de libération d'acheminement d'agents pharmaceutiques à travers des membranes, y compris l'épiderme ou les muqueuses d'un patient. Un agent pharmaceutique est lié de manière covalente à un modificateur chimique, via une liaison physiologiquement clivable, de telle façon que le transport et la libération de l'agent par la membrane soient améliorés.

L6 ANSWER 11 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1992017216 PCTFULL
TITLE (ENGLISH): DELIVERY OF X-RAY CONTRAST AGENTS USING RECEPTOR MEDIATED ENDOCYTOSIS
TITLE (FRENCH): ADMINISTRATION D'AGENTS DE CONTRASTE RADIOGRAPHIQUES A L'AIDE DE L'ENDOCYTOSE A MEDIATION PAR RECEPTEURS
INVENTOR(S): JOSEPHSON, Lee; JUNG, Chu; PALMACCI, Stephen
PATENT ASSIGNEE(S): ADVANCED MAGNETICS, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

| | | |
|------------|----|----------|
| WO 9217216 | A1 | 19921015 |
|------------|----|----------|

DESIGNATED STATES: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL NO SE

APPLICATION INFO.: WO 1992 032251 19920318
PRIORITY (ORIGINAL): US 1991 679520 19910400

ABEN The invention provides a method of **targeting** an x-ray contrast

agent to a specific population of cells or organ. **Targeting** may be accomplished by forming a complex of a radiopaque label with a saccharide capable of interacting with a cell receptor. The resulting complex may then be internalized into the specific population of cells or organ by receptor mediated endocytosis. In one embodiment of the invention, the radiopaque label may include a compound containing iodine and the saccharide may include arabinogalactan, galactan, or derivatives thereof. The invention provides a method for determining the metabolic viability or disease state of the **target** cells or organ by visualizing the extent, mode of uptake and excretion of the **targeted** x ray contrast agent by x ray or computer tomography.

ABF Procédé de ciblage sur un organe ou une population cellulaire spécifique d'un agent de contraste radiographique. Le ciblage peut s'effectuer par formation d'un complexe d'un traceur opaque aux rayons X et d'un saccharide apte à coopérer avec un récepteur cellulaire. On peut ensuite incorporer le complexe ainsi obtenu à l'organe ou à la population cellulaire spécifique au moyen d'une endocytose à médiation par récepteurs. Dans un mode de réalisation, le traceur opaque aux rayons X peut comprendre un composé contenant de l'iode et le saccharide peut comprendre de l'arabinogalactane, du galactane ou des dérivés de ceux-ci. On a également prévu un procédé de détermination de la viabilité métabolique ou de l'état pathologique de l'organe ou des cellules cible par la visualisation par tomographie radiographique ou commandée par ordinateur de l'étendue, du mode de fixation et de l'excrétion de l'agent de contraste radiographique cible.

56 ANSWER 12 OF 21 USPATFULL

ACCESSION NUMBER: 1999:136685 USPATFULL

TITLE: Pretargeting protocols for the enhanced localization of cytotoxins to **target** sites and cytotoxic combinations useful therefore

INVENTOR(S): Fritsberg, Alan R., Edmonds, WA, United States
Abrams, Paul G., Seattle, WA, United States
Reno, John M., Brier, WA, United States
Azworthy, Donald B., Brier, WA, United States
Graves, Scott S., Monroe, WA, United States
Kasina, Sudhakar, Kirkland, WA, United States

PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5976535 | | 19991102 |
| APPLICATION INFO.: | US 1995-468513 | | 19950606 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation in part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283312 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Cunningham, Thomas H. | | |
| LEGAL REPRESENTATIVE: | Seed and Berry LLP | | |
| NUMBER OF CLAIMS: | 3 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 13 Drawing Figure (s); 13 Drawing Page(s) | | |
| LINE COUNT: | 4278 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for **targeting** cytotoxins to **target** sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.

L6 ANSWER 14 OF 21 USPATEFUL

ACCESSION NUMBER: 1999:124443 USPATEFUL
TITLE: In vivo binding pair pretargeting
INVENTOR(S): Pomato, Nicholas, Frederick, MD, United States
McCabe, Richard P., West Chester, PA, United States
Hawkins, Gregory A., Madison, WI, United States
Bredehorst, Reinhard, Hamburg, Germany, Federal Republic of
Kin, Chong Ho, Rockville, MD, United States
Vogel, Carl-Wilhelm, Hamburg, Germany, Federal Republic of
PATENT ASSIGNEE(S): Per-Immune Holdings, Inc., Rockville, MD, United States (U.S. Corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5969006 | | 19991012 |
| APPLICATION INFO.: | US 1995-461267 | | 19950605 (8) |
| RELATED APPLN. INFO.: | Continuation in part of Ser. No. US 1993-149186, filed on 4 Nov 1993, now patented, Pat. No. US 5578289 which is a continuation-in-part of Ser. No. US 1992-846453, filed on 4 Mar 1992, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Green, Lora M. | | |
| LEGAL REPRESENTATIVE: | Gormley, Mary E. | | |
| NUMBER OF CLAIMS: | 2 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 59 Drawing Figure(s); 42 Drawing Page(s) | | |
| LINE COUNT: | 3962 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for in-vivo **targeting** a functional moiety in a patient by administering a **targeting** moiety coupled to an affinity component, wherein the **targeting** moiety has affinity for binding sites in a **target** area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the **target** area. Preferably the **targeting** moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.

L6 ANSWER 14 OF 21 USPATEFUL

ACCESSION NUMBER: 1999:113840 USPATEFUL
TITLE: Biotinidase resistant biotin-DOTA conjugates
INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. Corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5959905 | | 19990921 |
| APPLICATION INFO.: | US 1996-099940 | | 19960812 (8) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1995-351469, filed on 21 Feb | | |

DOCUMENT TYPE: 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biotinidase resistant biotin DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

16 ANSWER 15 OF 21 USPATFULL

ACCESSION NUMBER: 1998:9515 USPATFULL

TITLE: Fibrin binding peptide fragments of fibronectin

INVENTOR(S): Gold, Leslie I., New York, NY, United States

Rostagno, Agueda A., Elmhurst, NY, United States
 Baron, Martin, Oxford, United Kingdom
 Campbell, Iain D., Oxford, United Kingdom
 Williams, Michael J., Oxford, United Kingdom
 PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S.
 corporation)
 Isis Innovation Ltd., Oxford, England (non-U.S.
 corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 5792742 | | 19980811 |
| APPLICATION INFO.: | US 1994 283857 | | 19940801 (3) |
| RELATED APPLN. INFO.: | Continuation in part of Ser. No. US 1991-714134, filed on 14 Jun 1991, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE STATUS: | Granted | | |
| PRIMARY EXAMINER: | Fitzgerald, David L. | | |
| LEGAL REPRESENTATIVE: | Browdy and Neimark | | |
| NUMBER OF CLAIMS: | 13 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 57 Drawing Figure(s); 33 Drawing Page(s) | | |
| LINE COUNT: | 4177 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fibrin-binding molecules are provided which include at least one peptide essentially corresponding to one or both of the following portions of the natural fibronectin molecule. The first portion is that portion which includes the .sup.4 F1..sup.5 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the N-terminal 25.9 kDa proteolytic fragment. The second portion includes the .sup.10 F1..sup.11 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the C-terminal 11 kDa proteolytic fragment. Also disclosed are nucleic acid molecules encoding the fibrin-binding peptides, methods for making the peptides, methods for using the peptides in the diagnosis and treatment of cardiovascular, peripheral vascular, cerebrovascular, and other conditions associated with fibrin deposition, and assay methods for detecting a fibrin binding molecule and for measuring fibrin.

16 ANSWER 16 OF 41 USPATFULL

ACCESSION NUMBER: 97-4-628 USPATFULL

FIELD: Two step pretargeting methods using improved biotin active agent conjugates

INVENTOR(S): Reno, John M., Brier, WA, United States

PATENT ASSIGNEE(S) :

Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|--|--|------|--------------|
| PATENT INFORMATION: | US 5,309,946 | | 19970520 |
| APPLICATION INFO.: | US 1993-122979 | | 19930910 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned And Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283442 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Eisenschent, Frank C. | | |
| LEGAL REPRESENTATIVE: | Burns, Doane, Swecker & Mathis, L.L.P. | | |
| NUMBER OF CLAIMS: | 16 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 22 Drawing Figure(s); 22 Drawing Page(s) | | |
| LINE COUNT: | 4768 | | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | | |

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti ligand-**targeting** moiety conjugates, **target** cell retention enhancing moieties and additional methods are discussed.

66 ANSWER 17 OF 21 USPATFULL

ACCESSION NUMBER: 97:18284 USPATFULL
TITLE: Biotinidase resistant biotin-¹²⁵IOTA conjugates
INVENTOR(S): Azworthy, Donald B., Brier, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------------------|
| PATENT INFORMATION: | US 5608060 | | 19970304 |
| | WO 9325240 | | 19931223 |
| APPLICATION INFO.: | US 1995-351469 | | 19950221 (8) |
| | WO 1993-US5406 | | 19930607 |
| | | | 19950221 PCT 371 date |
| | | | 19950221 PCT 102(e) date |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned, each Ser. No. US which is a continuation in part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283442, issued on 1 Feb 1994 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Eisenschent, Frank C. | | |
| LEGAL REPRESENTATIVE: | Burns, Doane, Swecker & Mathis, L.L.P. | | |
| NUMBER OF CLAIMS: | 9 | | |

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figures; 10 Drawing Pages
LINE COUNT: 4732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

I6 ANSWER 18 OF 21 USPATFULL

ACCESSION NUMBER: 92:17918 USPATFULL
TITLE: Compositions and methods for enhanced drug delivery
INVENTOR(S): Hale, Ron L., Woodside, CA, United States
Lu, Amy, Los Altos, CA, United States
Solas, Dennis, San Francisco, CA, United States
Selick, Harold E., Belmont, CA, United States
Odenburg, Kevin R., Fremont, CA, United States
Zaffaroni, Alejandro C., Atherton, CA, United States
PATENT ASSIGNEE(S): Amymax Technologies N.V., Middlesex, England (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 5607691 | | 19970304 |
| APPLICATION INFO.: | US 1995-44918 | | 19950524 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1993-164293, filed on 9 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-77296, filed on 14 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-898218, filed on 12 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1993-9463, filed on 27 Jan 1994, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Levy, Neil S. | | |
| LEGAL REPRESENTATIVE: | Stevens, Lauren L. | | |
| NUMBER OF CLAIMS: | 5 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 5249 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

I6 ANSWER 19 OF 21 USPATFULL

ACCESSION NUMBER: 95:47701 USPATFULL
TITLE: Polymeric carriers for non-covalent drug conjugation
INVENTOR(S): Gustavson, Linda M., 19809 31st St., NE., Seattle, WA, United States 98155
Anderson, David C., 200 Lassen Dr., San Bruno, CA, United States 94066
Morgan, Jr., Alton C., 803 Driftwood Pl., Edmonds, WA, United States 98026

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5429195 | | 19950530 |
| APPLICATION INFO.: | US 1993 95915 | | 19930726 (2) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1990 248456, filed on 23 Sep 1988, now patented, Pat. No. US 5252713 | | |
| DOCUMENT TYPE: | Utility | | |

FILE SEGMENT: Granted
 PRIMARY EXAMINER: Russel, Jeffrey E.
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM:
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 1045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymeric carriers are polypeptides comprising at least one drug binding domain that non-covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired **target** cells to form immunconjugates that deliver a drug to the **target** cells in vivo. A polymeric carrier may be attached to a proteinaceous or a non-proteinaceous ligand or anti-ligand to form a conjugate useful in pretargeting protocols to deliver a drug to **target** cells in vivo. The carriers are derived from drug-binding proteins and produced through peptide synthesis or recombinant DNA technology.

I6 ANSWER 20 OF 21 USPATFULL

ACCESSION NUMBER: 93:85263 USPATFULL
 TITLE: Polymeric carriers for non-covalent drug conjugation
 INVENTOR(S): Morgan, Cr., Alton C., Edmonds, WA, United States
 Anderson, David C., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--------------------------------|------|--------------|
| PATENT INFORMATION: | US 1252713 | | 19931012 --- |
| APPLICATION INFO.: | US 1988-249456 | | 19880923 (7) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Russel, Jeffrey E. | | |
| LEGAL REPRESENTATIVE: | Burns, Doane, Swecker & Mathis | | |
| NUMBER OF CLAIMS: | 14 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 1034 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymeric carriers are polypeptides comprising at least one drug-binding domain that non-covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired **target** cells to form immunconjugates that deliver a drug to the **target** cells in vivo. The carriers are derived from drug binding proteins and produced through peptide synthesis or recombinant DNA technology.

I6 ANSWER 21 OF 21 USPATFULL

ACCESSION NUMBER: 93:70128 USPATFULL
 TITLE: Delivery of x-ray contrast agents using receptor mediated endocytosis
 INVENTOR(S): Jung, Chu, Arlington, MA, United States
 Palmacci, Stephen, Walpole, MA, United States
 Josephson, Lee, Arlington, MA, United States
 PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5141734 | | 19920925 1 |
| APPLICATION INFO.: | US 1991-079526 | | 19910402 (7) |
| RELATED APPL. INFO.: | continuation-in-part of Ser. No. US 1989-384991, filed on 28 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-228640, filed on 4 Aug 1988, now abandoned which is a | | |

Continuation in part of Ser. No. US 1987-07506, filed on 10 Feb. 1987, now patented, Pat. No. US 4877946 which is a continuation in part of Ser. No. US 1986-882044, filed on 7 Jul 1986, now patented, Pat. No. US 4779183

INVENTION TYPE: Utility
FILE STATUS: Granted
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: Hollinden, Gary E.
LEGAL REPRESENTATIVE: Bromberg & Sunstein
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 662
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method of **targeting** an x-ray contrast agent to a specific population of cells or organ. **Targeting** may be accomplished by forming a complex of a radiopaque label with a saccharide capable of interacting with a cell receptor. The resulting complex may then be internalized into the specific population of cells or organ by receptor mediated endocytosis. In one embodiment of the invention, the radiopaque label may include a compound containing iodine and the saccharide may include arabinogalactan, galactan, or derivatives thereof. The invention provides a method for determining the metabolic viability or disease state of the **target** cells or organ by visualizing the extent, mode of uptake and excretion of the **targeted** x-ray contrast agent by x-ray or computer tomography.